Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Researchers at KTH Royal Institute of Technology found that knocking out the gene ULK1 — which controls cellular recycling (autophagy) — dramatically boosts production of membrane proteins, a key bottleneck in drug development. Working with AstraZeneca, the team saw protein yields jump by up to 100%. The discovery could speed up drug discovery and cut R&D costs significantly.
Researchers at KTH Royal Institute of Technology, in collaboration with AstraZeneca, have found a surprising shortcut to producing more of the proteins that underpin drug discovery. By knocking out the gene ULK1 — which initiates autophagy, the process cells use to break down and recycle their own proteins — the team got human cells to churn out significantly higher quantities of hard-to-make membrane proteins. The best part? The cells were completely fine without it.
Membrane proteins are the targets of roughly 60% of all approved medicines, yet they're notoriously difficult to produce in useful quantities. Rather than boosting the cell's production machinery (the usual approach), the researchers took the counterintuitive route of disabling its "clean-up crew." Published in Cell Systems, the study showed the modified cells thrived and outperformed standard cells in protein output.
By the Numbers:
Why it matters: A reliable, scalable way to produce membrane proteins could meaningfully accelerate drug discovery pipelines and reduce R&D costs — with potential ripple effects for treatments targeting neurodegenerative diseases linked to protein buildup.